Article
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.
Scientific reports - 28 Feb 2022
Su Po-Lan, Chen Jung-Yueh, Chu Chang-Yao, Chen Yi-Lin, Chen Wan-Li, Lin Kuan-Yu, Ho Chung-Liang, Tsai Jeng-Shiuan, Yang Szu-Chun, Chen Chian-Wei, Wu Yi-Lin, Tseng Yau-Lin, Chang Chao-Chun, Yen Yi-Ting, Lin Chia-Ying, Lin Chien-Chung, Su Wu-Chou
Abstract excerpt
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC). This study aimed to assess whether the presence of targetable driver mutations affects the efficacy of the combination of immunotherapy and chemotherapy. We enrolled patients with early-stage operable NSCLC who received preoperative neoadjuvant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.